Recent Updates
Recently added Catalysts

Test drug

Phase 1

Bioequivalence | Small molecule | Other |Pfizer, Inc.|Last Updated: Jul 16, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment28

FDA Designations

No designations recorded

Clinical trial landscape

Test drug · 1 trial · 1 indication

Phase 1 1
NCT03821480Diflucan Bioequivalence Study For Transferring The ManufactureBioequivalence
COMPLETED28 Analytics
PHASE1COMPLETED
Diflucan Bioequivalence Study For Transferring The Manufacture
BioequivalenceUnlock trial analytics

Study Endpoints

Primary Endpoints

1.Area Under Curve [AUC]last of fluconazole in Whole blood
At pre-dose (immediately prior to dosing) and 0.16, 0.33, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 24, 48, 72 and 96 hours postdose.

Area Under Curve(AUC) will be evaluated with Winnonlin analysis(Linear trapezoidal linear interpolation).

2.Maximum Plasma Concentration [Cmax] of fluconazole in Whole blood
At pre-dose (immediately prior to dosing) and 0.16, 0.33, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 24, 48, 72 and 96 hours postdose.

Plasma concentrations of fluconazole will be assayed by a validated LC- MS/MS method.

Secondary Endpoints

1.AUCinf
At pre-dose (immediately prior to dosing) and 0.16, 0.33, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 24, 48, 72 and 96 hours postdose.
2.AUCt/AUCinf
At pre-dose (immediately prior to dosing) and 0.16, 0.33, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 24, 48, 72 and 96 hours postdose.
3.t½
At pre-dose (immediately prior to dosing) and 0.16, 0.33, 0.75, 1, 1.5, 2, 3, 5, 8, 12, 24, 48, 72 and 96 hours postdose.
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Fluconazole 50 mg, Manufacturer: AmboiseEXPERIMENTALTest drug
Fluconazole 50mg, Manufacturer:West RydeACTIVE_COMPARATORReference drug

Interventions

NameTypeDescription
Test drugDRUGFluconazole capsule 50 mg Manufacturer: West Ryde
Reference drugDRUGFluconazole capsule 50 mg Manufacturer: Amboise
Unlock Study Design Details

Eligibility Criteria

Age Range19 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria * Healthy male and subjects who are between the ages of 19 and 55 years. * Female subjects who are found not to be pregnant in physical examinations * BMI of 17.5 to 30.5 kg/m2; and a total body weight \>50 kg (110 lb). * Evidence of a personally signed and dated informed consent...

Countries:South Korea
Unlock Eligibility Criteria

Frequently asked questions about Test drug

What is Test drug used for?

Test drug is used for bioequivalence, meaning it is being studied to confirm that a manufactured version of the drug performs the same as a reference product. It is a small molecule being developed by Pfizer, Inc. for this purpose.

Who makes Test drug?

Pfizer, Inc. (NYSE: PFE) is developing Test drug. The company is conducting a clinical trial to support the transfer of the drug's manufacturing process, with the goal of demonstrating bioequivalence to the reference product.

What phase is Test drug in?

Test drug is in Phase 1 clinical development. It is an investigational drug being studied for bioequivalence, and it is not yet approved by regulatory authorities. The Phase 1 trial has been completed.

What clinical trials is Test drug in?

Test drug has one completed clinical trial, NCT03821480, titled "Diflucan Bioequivalence Study For Transferring The Manufacture." This Phase 1 study enrolled 28 healthy volunteers in South Korea and was active-controlled, meaning it compared the test drug against an active reference.

Is Test drug the same as Diflucan?

Test drug is being studied for bioequivalence to Diflucan, as indicated by the clinical trial title. The trial aims to confirm that the manufactured Test drug matches Diflucan's performance, but Test drug itself is a distinct product under investigation.